What is DMAC's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.45B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for DMAC?

P/E (TTM) is n/a and 52-week range is $5.25 to $10.42 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s DMAC figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for DMAC?

The company profile lists net income (TTM) near $-39M, EPS (TTM) near $-0.72 when available from the market-data feed. Figures are informational and may lag live markets.

Where is DiaMedica Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Minneapolis, Minnesota, US, 53.9M shares outstanding, ISIN CA25253X2077 when available from company profile and filing metadata.

DiaMedica Therapeutics Inc

$DMAC

Health Care · Biotechnology

IR Run Scenarios

$8.33

+4.00%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. The company is headquartered in Minneapolis, Minnesota and currently employs 35 full-time employees. The company went IPO on 2008-01-04. The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.

Employees

Website

www.diamedica.com/

IPO

2008-01-04

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)